Development of Delivery Systems Enhances the Potency of Cell-Based HIV-1 Therapeutic Vaccine Candidates

Table 3

Flow cytometry analysis of gene expression under mechanical and chemical treatments in MSCs.

Methods	Percentage
GFP expression using both TurboFect™ and Lipofectamine transfection reagents
pEGFP-Nef expression using both TurboFect™ and Lipofectamine transfection reagents
pEGFP-Nef expression using equiaxial cyclic stretch (30 minutes, strain rates of 10%, and frequency 1 Hz)
pEGFP-N1 expression using equiaxial cyclic stretch (30 minutes, strain rates of 10%, and frequency 1 Hz)
pEGFP-N1 and pEGFP-Nef expression using equiaxial cyclic stretch (30 minutes, strain rates of 5%, and frequency 1 Hz)	6-7%
pEGFP-Nef expression using a combination of TurboFect™ transfection reagent and equiaxial cyclic stretch (30 minutes, strain rates of 10%, and frequency 1 Hz)
pEGFP-N1 expression using a combination of TurboFect™ transfection reagent and equiaxial cyclic stretch (30 minutes, strain rates of 5%, and frequency 1 Hz)
pEGFP-Nef expression using a combination of TurboFect™ transfection reagent and equiaxial cyclic stretch (30 minutes, strain rates of 10%, and frequency 1 Hz)
pEGFP-N1 expression using a combination of Lipofectamine transfection reagent and equiaxial cyclic stretch (30 minutes, strain rates of 5%, and frequency 1 Hz)
pEGFP-Nef expression using a combination of Lipofectamine transfection reagent two times at 48 h intervals and equiaxial cyclic stretch (30 minutes, strain rates of 10%, and frequency 1 Hz)
pEGFP-Nef expression using a combination of Lipofectamine transfection reagent two times at 48 h intervals and equiaxial cyclic stretch (30 minutes, strain rates of 10%, and frequency 1 Hz)